NeOnc Technologies Holdings (NASDAQ:NTHI) is strengthening its boardroom at a pivotal moment in its brain-cancer drug ...
BioNTech’s experimental cancer treatment combined with Merck’s Keytruda failed to significantly delay disease progression compared with Keytruda alone.
Revolution Medicines' daraxonrasib is the first drug that can broadly tackle one of the main drivers of pancreatic cancer.
Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline ...
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...
Monash University’s Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a ...
Florida Cancer Specialists & Research Institute, LLC (FCS) is celebrating its pivotal role in the development of two recently ...
A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new two-step method promises to revolutionize targeted cancer drug development by ...
The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...
Lauren writes about healthcare AI data interoperability, the science behind public health recommendations, and pharmaceutical advances in the rare disease space. In a rare move, nonprofit organization ...
The portfolio consists of eight drug candidates originating from Innovent Biologics and four discovery programmes proposed by Pfizer. Credit: Jonathan Weiss / Shutterstock.com. · Pharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results